Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk None. and Cholesterol Treatment Trialists’ (CTT) Collaboration None., (2024), Lancet Diabetes Endocrinol, 12, 306 - 319
Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study.
Mihaylova B. et al, (2024), Lancet Reg Health Eur, 40
Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP).
Herrington WG. et al, (2023), Kidney Int Rep, 8, 1489 - 1495
Accelerating clinical trials: time to turn words into action.
Landray MJ. et al, (2023), Lancet, 402, 165 - 168
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK.
Zhou J. et al, (2023), Pharmacoeconomics
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet, 400, 832 - 845
Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.
Pitcher A. et al, (2022), Lancet
Individual participant data meta-analysis of muscle symptoms in large-scale randomised double-blind trials of statin therapy
BAIGENT C. et al, (2022), The Lancet
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368
Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy.
Cholesterol Treatment Trialists' Collaboration None., (2022), Clin Trials
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2022), Lancet, 399, 665 - 676
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2022), Lancet, 399, 143 - 151
CALIBRATING CARDIOVASCULAR DISEASE POLICY MODEL USING LARGE COHORT DATA
Wu R. et al, (2022), VALUE IN HEALTH, 25, S16 - S16
Impact of cardiovascular events on primary and hospital care costs: findings from UK Biobank study
Zhou J. et al, (2022), EUROPEAN HEART JOURNAL, 43, 2852 - 2852
Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials.
Staplin N. et al, (2021), EClinicalMedicine, 41
A model of lifetime health outcomes in cardiovascular disease based on clinical trials and large cohorts
Wu R. et al, (2021), EUROPEAN HEART JOURNAL, 42, 3149 - 3149
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2021), Lancet, 397, 2049 - 2059
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2021), Lancet, 397, 1637 - 1645
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2021), Lancet, 397, 605 - 612